Matthew T. Wiley
CIK 1759703 · Chief Commercial Officer · last filed 2026-06-26
Matthew T. Wiley is a Chief Commercial Officer who has filed 35 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing shows the insider sold $129.1K of DFTX on Jun 26, 2026. Across all open-market trades the lifetime net is −$85.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.33M
6
35
-$85.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Commercial Officer | 174,633 | $41.96 | $7.33M | -$129.1K | 3 | 2026-06-26 |
| BTAI | Chief Commercial Officer | 1,580 | $0.84 | $1.3K | -$6.6K | 8 | 2025-04-01 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Commercial Officer | — | $15.00 | — | $0 | 1 | 2025-03-18 |
| VYNE | Chief Commercial Officer | 121 | $28.56 | $3.5K | $0 | 6 | 2021-07-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Commercial Officer | 352,425 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Chief Commercial Officer | 114,074 | — | — | $50.5K | 6 | 2020-03-03 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | DFTX | Sell (S) | −2,867 | -$129.1K | EDGAR |
| 2026-06-25 | DFTX | Notice (144) | −2,867 | -$120.8K | EDGAR |
| 2026-06-22 | DFTX | Grant (A) | +62,500 | $0 | EDGAR |
| 2026-02-05 | DFTX | Grant (A) | +115,000 | $0 | EDGAR |
| 2025-04-01 | BTAI | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-03 | BTAI | Notice (144) | −6,272 | -$3.4K | EDGAR |
| 2024-10-03 | BTAI | Mixed | +14,978 | -$3.4K | EDGAR |
| 2024-09-17 | BTAI | Mixed | +535 | -$149 | EDGAR |
| 2024-09-17 | BTAI | Exer (M) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.